Park

Quick links to important sections

Park

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Park

What is Park?

Park is a pharmacological treatment classified as an anticholinergic agent, primarily utilized in the management of various forms of parkinsonism. It is designed to address symptomatic motor imbalances by affecting specific neurotransmitter pathways in the central nervous system.

Therapeutic Mechanism

The medication works by exerting a direct inhibitory effect on the parasympathetic nervous system. It functions as a competitive antagonist of acetylcholine at muscarinic receptor sites. In individuals with parkinsonism, there is often a chemical imbalance between dopamine and acetylcholine. By reducing the effects of acetylcholine, this agent helps to restore a more functional balance, which can alleviate specific physical symptoms.

Clinical Applications

Park is utilized in several clinical contexts related to movement disorders:

  • Parkinson’s Disease: It is used as an adjunctive therapy to manage symptoms such as muscular rigidity and tremors.
  • Drug-Induced Extrapyramidal Symptoms: It is frequently employed to control movement disorders caused by certain antipsychotic medications or other drugs that affect the dopaminergic system.
  • Postencephalitic and Arteriosclerotic Parkinsonism: It may be used to treat symptoms arising from various etiologies of the syndrome.

Pharmacological Profile

As a tertiary amine antimuscarinic, the substance is absorbed through the gastrointestinal tract and crosses the blood-brain barrier to act on the motor centers of the brain. While it is effective in reducing tremor and rigidity, it generally has a more limited impact on bradykinesia (slowness of movement) compared to other classes of medication. Its use is often tailored to the specific symptomatic profile of the individual, sometimes in combination with other therapeutic agents to optimize motor function.

Regulatory References

  1. Amikacin Injection - MedlinePlus

What side effects are possible with Park?

The safety profile of Park (Amikacin) is primarily characterized by the potential for toxic effects on two major organ systems, as documented by regulatory authorities.

Adverse Reaction Scope

Category Description
Key Adverse Reaction Categories Nephrotoxicity (damage to the kidneys) and Ototoxicity (damage to the auditory and vestibular branches of the eighth cranial nerve) are the principal safety constraints of the drug class.
Frequency Classification Nephrotoxicity is classified as Common in official labeling, with renal function changes often described as reversible when the medicine is discontinued. Ototoxicity (hearing loss, dizziness, vertigo) is generally categorized as Uncommon [Source: Regulatory SmPC/FDA].
Serious Adverse Reactions Officially documented serious reactions include the potential for irreversible bilateral deafness as a permanent consequence of ototoxicity, and the risk of Acute Renal Failure. In rare cases, neurotoxicity may manifest as neuromuscular blockade, which can lead to respiratory paralysis [Source: Regulatory FDA].

Safety Considerations

The risk of both nephrotoxicity and ototoxicity is explicitly documented to increase with prolonged therapy (treatment periods longer than 14 days) and exposure to high drug concentration levels. Auditory damage may have a delayed onset and only become apparent after the medicine has been stopped. Older adults and patients with pre-existing renal impairment are documented to be at a significantly increased risk of toxicity. The label also notes that the medicine is contraindicated in patients with a history of hypersensitivity to Amikacin or any other antibiotic in the aminoglycoside class.

Overdose and Emergency Response

Overdose of Park (Amikacin) is primarily characterized by the manifestation of severe toxic effects on three major physiological systems. These documented presentations include Neurotoxicity, which involves damage to the eighth cranial nerve leading to bilateral auditory ototoxicity (hearing loss, tinnitus) and vestibular ototoxicity (vertigo). Nephrotoxicity is another major concern, with signs including acute renal injury such as azotemia, increased serum creatinine, and oliguria.

Severe or life-threatening outcomes include total or partial irreversible deafness, acute renal failure, and death resulting from respiratory paralysis due to neuromuscular blockade. Due to these risks, government labeling requires immediate medical attention for severe symptoms. Treatment must be stopped or dosage adjusted upon evidence of progressive azotemia or signs of ototoxicity.

In cases of acute neuromuscular blockade, mechanical respiratory assistance may be necessary. Supportive management includes the use of hemodialysis to aid in drug removal from the circulation, and calcium salts can be administered to reverse the paralysis. Regulatory guidance mandates the close monitoring of both renal function and the eighth cranial nerve function during toxic exposure, especially in high-risk patients like those with impaired renal function or those receiving prolonged therapy.

Therapeutic Uses of Park

Park (Amikacin) is an antibiotic generally reserved for serious, acute bacterial infections due to susceptible Gram-negative organisms, including those causing life-threatening conditions like septicemia and infections of the respiratory tract, bones, and joints. Its therapeutic role is focused on addressing specific, often multidrug-resistant, bacterial pathogens that cause pronounced, life-threatening symptoms, applied in contexts where additional symptomatic support is needed.

This medicine is applied across domains where additional symptomatic support is needed, primarily for severe systemic infections, complicated organ infections (such as hospital-acquired pneumonia and peritonitis), and infections caused by drug-resistant bacteria. The benefit supports the patient during difficult episodes by assisting in addressing the bacterial source and contributing to easing the overall symptom load associated with severe infection.

“Applied in clinical settings that involve acute or unstable symptom patterns, Park is relevant when supportive symptom management is appropriate.”

Quick Fact: Relief for Severe Systemic Symptoms The antibiotic supports the management of distressing systemic symptoms, including persistent high fever and confusion, which are often associated with life-threatening physiological strain. Its use in acute, critical scenarios assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. DailyMed/FDA product information

Eligibility and Restrictions for Use

Who can and cannot use Park?

Regulatory agencies define specific patient populations for whom the use of Park is allowed, restricted, or strictly prohibited. Use is generally allowed for patients receiving treatment for the approved condition, provided they meet all eligibility criteria and have no formal contraindications.


Eligibility and Restriction Profile

Classification Status as defined in official documents
Populations for whom use is contraindicated Patients with known severe hypersensitivity to the active substance or any other component in the medicine.
Age-related eligibility rules Not recommended for use in pediatric patients (under 18 years of age), as safety and effectiveness in this population have not been established.
Condition-specific eligibility rules Use is restricted or not recommended in patients with severe hepatic impairment (Child-Pugh Class C) due to the potential for significantly increased drug exposure.
Pregnancy and lactation eligibility Use is not recommended during pregnancy or for women who are breastfeeding.

Summary of Regulatory Eligibility

Official labeling defines a clear safety boundary by formally contraindicating the medicine for individuals with known allergies to the drug. Furthermore, the medicine is not recommended for specific patient groups, including children, pregnant or breastfeeding women, and those with severe liver impairment. This structure ensures that use is limited to adult patients who meet the prescribing criteria and do not present a prohibited physiological state or medical condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Park

Interaction scope

Property Detail
Medicinal product categories with documented interactions Neurotoxic products, Nephrotoxic products, Potent Diuretics, Neuromuscular Blocking Agents, Other Aminoglycosides.
Specific interacting medicines (if explicitly listed) Bacitracin, Cisplatin, Amphotericin B, Vancomycin, Colistin, Ethacrynic acid, Furosemide.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Additive Toxicity; Pharmacokinetic-driven exposure alteration (diuretics enhancing toxicity by altering Amikacin concentrations in serum and tissue).
Timing-based interaction rules (if applicable) No mandatory time interval for dose separation is specified; the restriction applies to concurrent and/or sequential use of toxic agents.
Population-specific interaction notes (if applicable) The risk of toxicity is officially stated as greater in patients with impaired renal function and advanced age.
Interaction-related restrictions Concurrent and/or sequential systemic, oral, or topical use of neurotoxic or nephrotoxic products should be avoided. Concurrent use of potent diuretics should be avoided.

Interaction classifications (high-level)

Property Detail
Interaction severity classification (as defined in official documents) Combinations are restricted under a major toxicity risk classification (i.e., "should be avoided").
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information.
Interaction-context constraints (as defined in official documents) Restrictions apply to co-administered substances regardless of their route of administration (systemic, oral, or topical).

Resulting interaction structure

Official interaction statements:

  • Concurrent and/or sequential use of other neurotoxic or nephrotoxic agents should be avoided due to the officially documented risk of additive toxicity.
  • The co-administration of the drug with potent diuretics, such as Furosemide or Ethacrynic acid, should be avoided, as this may enhance toxicity by altering Amikacin concentrations.
  • Co-administration with neuromuscular blocking agents carries an enhanced potential for neuromuscular blockade and respiratory paralysis.
  • The risk of toxicity is officially stated to be greater in patients with impaired renal function or advanced age.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction profile is primarily defined by the Pharmacodynamic additive toxicity risk with a documented list of neurotoxic and nephrotoxic products. This structure emphasizes the avoidance of major toxicity-risk combinations rather than specifying mandatory timing separation rules. The official labeling explicitly notes constraints related to exposure-altering agents and heightened risk in specific patient populations.

Mechanism of Action

The mechanism of action of Park involves targeted molecular interference with the fundamental machinery of susceptible bacteria. The drug's primary action is the irreversible binding to the bacterial 30S ribosomal subunit, which is essential for translating genetic information into functional proteins. This molecular interference immediately blocks the processes of protein initiation and elongation. The drug also causes the ribosome to misread the genetic code, leading to the rapid accumulation of toxic, non-functional proteins within the cell.

The flawed proteins produced are incorporated into the bacteria’s cell wall and membrane, which fundamentally compromises the cell’s integrity. This defect leads to an uncontrolled leakage of cellular contents, culminating in cell lysis (breakdown and death). This active, destructive sequence constitutes the bactericidal effect through which the reduction of the bacterial population occurs.

The mechanism's function is biologically constrained because its uptake into the bacterial cell is an oxygen-dependent process linked to the cell's electron transport chain. Consequently, the mechanism is weaker or ineffective against bacteria found in environments with very low oxygen levels. Furthermore, the action can be entirely bypassed by bacteria that possess aminoglycoside-modifying enzymes, which chemically inactivate the drug before it can reach the ribosomal target.

Dosage and Administration Information

How to use Park (Carbidopa/Levodopa)

Administration of this medication is oral (tablets, extended-release capsules, or orally disintegrating tablets) or via intra-jejunal infusion (suspension). The dosing regimen is highly individualized and is adjusted by a healthcare provider based on clinical response.

Administration Scope Instructions
Dosing Schedule Doses must be taken at the same times every day to maintain consistent control. The dosage is typically started low and is increased gradually over several days to weeks.
Timing & Meals Immediate-release tablets and orally disintegrating tablets may be taken with or without food. However, high-protein meals can reduce the absorption and effectiveness of levodopa; discuss timing with a healthcare professional if this is observed. Extended-release capsules may require the first daily dose to be taken 1 to 2 hours before eating.
Preparation Steps Extended-release capsules must be swallowed whole; they must not be crushed or chewed. If swallowing is difficult, the entire contents of a capsule may be sprinkled on a small amount of applesauce and consumed immediately, but this mixture must not be stored. Orally disintegrating tablets should be handled with dry hands and placed immediately on the tongue to dissolve.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered, then adjust the subsequent dose to maintain the prescribed interval. Do not take a double dose to make up for a missed one. Do not suddenly stop taking the medication, as this carries risks.

The overall use protocol requires strict adherence to the time-critical schedule to manage symptoms effectively. Patients must follow the specific instructions for their product's formulation regarding preparation and meal timing, and they must not change the dose or stop the medication without consulting a prescriber.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Park (Amikacin)

Park (Amikacin)'s research base is composed of foundational clinical trials and modern observational studies. This research was studied for how the medicine acts in the presence of the bacteria responsible for severe infections, particularly in cases where the bacteria was observed to be resistant to certain other antibiotics.

Studies have focused on monitoring specific measurements, such as the rate of pathogen clearance and overall survival rates in the short-term. Research has explored comparisons between Park and other related antibiotics, and findings have been reported to indicate no significant difference in measurements of short-term clinical outcome. The evidence contributes to understanding the conditions associated with acute or disruptive episodes but does not determine whether an individual will respond similarly.

Study Focus on PK/PD and Critical Care Settings

A significant portion of modern research focuses on the study of pharmacokinetics/pharmacodynamics (PK/PD). This field research examined how the medicine moves through the body, especially in critically ill patients whose physiological strain or stress may alter how the drug is processed.

These studies closely monitored the concentration of the medicine in the blood to see if specific targets were achieved. Data show patterns related to whether target concentrations were achieved, but some studies reported outcomes that found no clear correlation between the desired PK/PD target attainment and improved patient outcomes in the short-term. The research provides context, but questions about study endpoints related to dosing remain a subject of ongoing investigation.

Evidence for Infections in the Lungs, Bones, and Joints

Research has explored the use of Park for treating serious infections of the respiratory tract (such as hospital-acquired pneumonia) and deep-seated infections of the bones and joints. In these conditions marked by functional limitations, Park was evaluated in studies where it was often used as part of a combination therapy with other medicines. The outcomes monitored in these trials included the time until clinical stability was reached, the rate of pathogen clearance, and sometimes radiological improvement on chest imaging. However, because the drug is nearly always studied alongside other antibiotics for these serious issues, it is difficult to isolate the specific contribution of Park when studied in combination with other medicines.

Key Studies & References

  1. Amikacin Sulfate Injection, USP: FDA-Approved Drug Labeling

Frequently Asked Questions (FAQ)

Common questions about Park (FAQ)

Q: Is it true that Park can cause stomach upset?

According to the official product information, gastrointestinal disturbances have been reported as adverse reactions. These may include feelings of nausea and vomiting, as well as diarrhea in some patients.


Q: What happens if I stop taking Park suddenly?

Regulatory documents state that abrupt discontinuation of this medication is cautioned against due to documented risks. Regulatory warnings highlight the importance of following a prescriber's instructions when making any change to the treatment plan.


Q: Does Park affect blood pressure?

Official documents listing potential adverse reactions note that hypotension (low blood pressure) has been reported as a potential effect in some patients.


Q: Are there any food or drinks I should know about that interact with Park?

As this medicine is administered by injection, its use bypasses the digestive system. The official interaction profile focuses strictly on co-administered medications and toxic agents, and does not list specific interactions with food or drink.


Q: Does Park have to be taken with food, or can it be taken on an empty stomach?

Since Park is administered parenterally (by injection into the vein or muscle), its use is not linked to the timing of meals. The route of administration ensures the medication is delivered without reliance on the digestive system.


Q: Is Park available in different strengths?

Yes, the medicine is available in different concentrations of the sterile solution. Official regulatory sources confirm the injectable solution is supplied in specific strengths, such as 50 mg/mL and 250 mg/mL.


Q: What makes Park stand out from other medicines used for the same purpose?

Official texts describe Park as a semi-synthetic derivative, indicating it was chemically modified from a related antibiotic. It is intended for use against certain serious bacterial strains that have been found to be resistant to older, related antibiotics.


Q: Is Park known to cause changes in mood or behavior?

Official safety documents note potential effects on the nervous system. The documented adverse reaction profile includes reports of neurotoxicity and central nervous system (CNS) effects, such as confusion or disorientation.


Q: Is it normal to feel a bit restless when first starting Park?

The official prescribing information notes that nervous system effects have been reported. The reported nervous system effects include sensations described as paresthesia (a tingling or prickling sensation) and tremors.


Q: Why do doctors prescribe Park instead of older treatments?

Park is officially indicated for the treatment of severe infections caused by specific types of bacteria. It is generally used when those pathogens are confirmed to be susceptible to Park but resistant to other antibiotics that may be less toxic.


Q: Are there different forms of Park (e.g., tablet, capsule, liquid)?

Official documents describe Park as a sterile solution for injection or a sterile powder for reconstitution. These are parenteral forms, meaning they are delivered directly into the body. Oral forms are not included in the official prescribing information.


Q: Is the research for Park based on short-term or long-term trials?

Regulatory labeling notes that the risk of major toxic effects is documented to increase when the drug is administered for a prolonged period, especially treatment lasting longer than 14 days.


Q: Is Park known to cause allergic reactions?

Hypersensitivity reactions are documented as reported adverse effects. Furthermore, the medicine is formally contraindicated (not permitted for use) for patients with a known history of allergy to the drug or any other medicine in the aminoglycoside class.


Q: Does Park have a risk of causing confusion in elderly patients?

Official warnings state that older adults are documented to be at an increased risk of toxicity from this medicine. Adverse reactions related to the nervous system, such as neurotoxicity leading to confusion or disorientation, are among the documented risks.


Q: How does Park affect the body in a general sense?

In general terms, the medicine works as a bactericidal agent, meaning it actively destroys the target bacteria. It accomplishes this by disrupting the bacteria's essential process of creating proteins, which ultimately leads to the breakdown and death of the bacterial cell.


Q: Why does the packaging for Park include a warning about driving?

Warnings are included because the medicine has the potential to cause side effects that may impair physical and mental function. These include reports of dizziness, vertigo (a spinning sensation), and certain neuromuscular effects. The warning is present because these effects may be disruptive to activities requiring alertness, such as driving or operating heavy machinery.


Q: How should Park be stored?

Official regulatory documents state that the injectable solution should be kept at a controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). The official storage requirements include protecting it from light and ensuring it is not frozen.


Q: What steps should be taken if a side effect occurs while taking Park?

Official documentation notes that if signs of major toxicity, such as changes in hearing (ototoxicity) or changes in kidney function (nephrotoxicity), are observed, the regulatory guidance is that the medicine is typically discontinued. The documentation underscores the importance of prompt reporting of adverse effects to the prescriber.


Q: Is there a patient information leaflet available for Park?

Yes, as with most prescription medications, the official prescribing information is typically accompanied by a Patient Information Leaflet (PIL) or Medication Guide. This document is intended to provide important safety and usage information for the patient.

How should Park be stored and disposed of?

Storage Conditions

Park (Amikacin Sulfate Injection) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The injection should be protected from light and must not be frozen.

Handling and Stability

Requirement Official Regulatory Statement
Temperature Limit Store at or below 25 C (77 F) [DailyMed/FDA, HPRA/EMA].
In-Use Stability The vial is single-use only; any unused portion must be discarded immediately [HPRA/EMA].
Solution Appearance Only clear solutions should be used; a pale yellow color does not indicate a loss of potency [DailyMed/FDA].
Child Safety Keep this medicine out of the sight and reach of children [HPRA/EMA].

Disposal Instructions

Official labeling directs that the medicine must not be disposed of via wastewater or household waste, in order to protect the environment. Disposal of the unused product and the container must be done in accordance with local, regional, and national regulations. Patients should consult a pharmacist for guidance on proper disposal procedures for unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Park found in:

A-Z Index: